The Role of Vitamin D in Disease Progression in Early Parkinson's Disease

Isobel Sleeman; Terry Aspray; Rachael Lawson; Shirley Coleman; Gordon Duncan; Tien K Khoo; Inez Schoenmakers; Lynn Rochester; David Burn; Alison Yarnall

doi:10.3233/JPD-171122

The Role of Vitamin D in Disease Progression in Early Parkinson's Disease

Isobel Sleeman^* (Corresponding Author), Terry Aspray, Rachael Lawson, Shirley Coleman, Gordon Duncan, Tien K Khoo, Inez Schoenmakers, Lynn Rochester, David Burn, Alison Yarnall

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

53 Citations (Scopus)

4 Downloads (Pure)

Abstract

BACKGROUND: Previous cross-sectional studies have shown that Parkinson's disease (PD) patients have lower serum 25-hydroxy vitamin D (25(OH)D) concentrations than controls. Vitamin D deficiency was associated with increased disease severity and cognitive impairment in prevalent PD patients.

OBJECTIVE: The aim of the study was to determine 25(OH)D in newly diagnosed PD and age-matched controls and to assess if there was an association with clinical outcomes (disease severity, cognition and falls) over the 36-month follow up period.

METHODS: A prospective observational study of newly diagnosed PD patients in the North East of England with age-matched controls (PD, n = 145; control, n = 94). Serum 25(OH)D was assessed at baseline and 18 months. Participants underwent clinical assessment at baseline, 18 and 36 months. One hundred and ten participants with PD also took part in a prospective falls study.

RESULTS: Mean serum 25(OH)D concentrations were lower in PD than control participants at baseline (44.1±21.7 vs. 52.2±22.1 nmol/L, p < 0.05) and 18 months (44.2±23.6 vs. 55.7±28.8 nmol/L, p < 0.05). Baseline serum 25(OH)D concentration, age, motor score and dosage of dopaminergic medication were significant predictors of variance of motor severity at 36 months ((ΔR2 = 0.039, F = 6.6, p < 0.01). Serum 25(OH)D was not associated with cognition or falls during the follow up period.

CONCLUSIONS: Patients with incident PD had significantly lower serum 25(OH)D concentrations than age-matched controls, which may have implications in terms of bone health and fracture risk. There was a small but significant association between vitamin D status at baseline and disease motor severity at 36 months.

Original language	English
Pages (from-to)	669-675
Number of pages	7
Journal	Journal of Parkinson's Disease
Volume	7
Issue number	4
DOIs	https://doi.org/10.3233/JPD-171122
Publication status	Published - 1 Nov 2017

Bibliographical note

The authors acknowledge the study funders, Parkinson’s UK (J-0802), Newcastle University
Lockhart Parkinson’s Disease fund and the Newcastle Biomedical Research Centre. The research was supported by the National Institute of Health Research (NIHR) Newcastle Biomedical Research Unit based at Newcastle upon Tyne Hospitals NHS Foundation Trust/Newcastle University. The research was also supported by NIHR Newcastle CRF Infrastructure funding. Newcastle University acknowledge the support of the NIHR, through the Dementias and Neurodegenerative Diseases Research Network. IS was supported by a NIHR clinical fellowship. The authors would like to thank Sarah Meadows and her colleagues Nutritional Biomarker Analysis laboratory at MRC Elsie Widdowson Laboratory for the analyses of 25 hydroxyvitamin D. The views expressed are those of the authors and
not necessarily those of the NHS, the NIHR, or the Department of Health.

Keywords

balance
cognition
disease progression
fall
25-hydroxy vitamin D
Parkinson's disease
vitamin D

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3233/JPD-171122Licence: CC BY

Sleeman et al JPD The role of Vitamin VOR
This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) https://creativecommons.org/licenses/by/4.0/
Final published version, 156 KBLicence: CC BY

Cite this

@article{0028dc2cee6b48a599b9b22aa752edfb,

title = "The Role of Vitamin D in Disease Progression in Early Parkinson's Disease",

abstract = "BACKGROUND: Previous cross-sectional studies have shown that Parkinson's disease (PD) patients have lower serum 25-hydroxy vitamin D (25(OH)D) concentrations than controls. Vitamin D deficiency was associated with increased disease severity and cognitive impairment in prevalent PD patients.OBJECTIVE: The aim of the study was to determine 25(OH)D in newly diagnosed PD and age-matched controls and to assess if there was an association with clinical outcomes (disease severity, cognition and falls) over the 36-month follow up period.METHODS: A prospective observational study of newly diagnosed PD patients in the North East of England with age-matched controls (PD, n = 145; control, n = 94). Serum 25(OH)D was assessed at baseline and 18 months. Participants underwent clinical assessment at baseline, 18 and 36 months. One hundred and ten participants with PD also took part in a prospective falls study.RESULTS: Mean serum 25(OH)D concentrations were lower in PD than control participants at baseline (44.1±21.7 vs. 52.2±22.1 nmol/L, p < 0.05) and 18 months (44.2±23.6 vs. 55.7±28.8 nmol/L, p < 0.05). Baseline serum 25(OH)D concentration, age, motor score and dosage of dopaminergic medication were significant predictors of variance of motor severity at 36 months ((ΔR2 = 0.039, F = 6.6, p < 0.01). Serum 25(OH)D was not associated with cognition or falls during the follow up period.CONCLUSIONS: Patients with incident PD had significantly lower serum 25(OH)D concentrations than age-matched controls, which may have implications in terms of bone health and fracture risk. There was a small but significant association between vitamin D status at baseline and disease motor severity at 36 months.",

keywords = "balance, cognition, disease progression, fall, 25-hydroxy vitamin D, Parkinson's disease, vitamin D",

author = "Isobel Sleeman and Terry Aspray and Rachael Lawson and Shirley Coleman and Gordon Duncan and Khoo, {Tien K} and Inez Schoenmakers and Lynn Rochester and David Burn and Alison Yarnall",

note = "The authors acknowledge the study funders, Parkinson{\textquoteright}s UK (J-0802), Newcastle University Lockhart Parkinson{\textquoteright}s Disease fund and the Newcastle Biomedical Research Centre. The research was supported by the National Institute of Health Research (NIHR) Newcastle Biomedical Research Unit based at Newcastle upon Tyne Hospitals NHS Foundation Trust/Newcastle University. The research was also supported by NIHR Newcastle CRF Infrastructure funding. Newcastle University acknowledge the support of the NIHR, through the Dementias and Neurodegenerative Diseases Research Network. IS was supported by a NIHR clinical fellowship. The authors would like to thank Sarah Meadows and her colleagues Nutritional Biomarker Analysis laboratory at MRC Elsie Widdowson Laboratory for the analyses of 25 hydroxyvitamin D. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.",

year = "2017",

month = nov,

day = "1",

doi = "10.3233/JPD-171122",

language = "English",

volume = "7",

pages = "669--675",

journal = "Journal of Parkinson's Disease",

issn = "1877-7171",

publisher = "IOS Press",

number = "4",

}

TY - JOUR

T1 - The Role of Vitamin D in Disease Progression in Early Parkinson's Disease

AU - Sleeman, Isobel

AU - Aspray, Terry

AU - Lawson, Rachael

AU - Coleman, Shirley

AU - Duncan, Gordon

AU - Khoo, Tien K

AU - Schoenmakers, Inez

AU - Rochester, Lynn

AU - Burn, David

AU - Yarnall, Alison

N1 - The authors acknowledge the study funders, Parkinson’s UK (J-0802), Newcastle University Lockhart Parkinson’s Disease fund and the Newcastle Biomedical Research Centre. The research was supported by the National Institute of Health Research (NIHR) Newcastle Biomedical Research Unit based at Newcastle upon Tyne Hospitals NHS Foundation Trust/Newcastle University. The research was also supported by NIHR Newcastle CRF Infrastructure funding. Newcastle University acknowledge the support of the NIHR, through the Dementias and Neurodegenerative Diseases Research Network. IS was supported by a NIHR clinical fellowship. The authors would like to thank Sarah Meadows and her colleagues Nutritional Biomarker Analysis laboratory at MRC Elsie Widdowson Laboratory for the analyses of 25 hydroxyvitamin D. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - BACKGROUND: Previous cross-sectional studies have shown that Parkinson's disease (PD) patients have lower serum 25-hydroxy vitamin D (25(OH)D) concentrations than controls. Vitamin D deficiency was associated with increased disease severity and cognitive impairment in prevalent PD patients.OBJECTIVE: The aim of the study was to determine 25(OH)D in newly diagnosed PD and age-matched controls and to assess if there was an association with clinical outcomes (disease severity, cognition and falls) over the 36-month follow up period.METHODS: A prospective observational study of newly diagnosed PD patients in the North East of England with age-matched controls (PD, n = 145; control, n = 94). Serum 25(OH)D was assessed at baseline and 18 months. Participants underwent clinical assessment at baseline, 18 and 36 months. One hundred and ten participants with PD also took part in a prospective falls study.RESULTS: Mean serum 25(OH)D concentrations were lower in PD than control participants at baseline (44.1±21.7 vs. 52.2±22.1 nmol/L, p < 0.05) and 18 months (44.2±23.6 vs. 55.7±28.8 nmol/L, p < 0.05). Baseline serum 25(OH)D concentration, age, motor score and dosage of dopaminergic medication were significant predictors of variance of motor severity at 36 months ((ΔR2 = 0.039, F = 6.6, p < 0.01). Serum 25(OH)D was not associated with cognition or falls during the follow up period.CONCLUSIONS: Patients with incident PD had significantly lower serum 25(OH)D concentrations than age-matched controls, which may have implications in terms of bone health and fracture risk. There was a small but significant association between vitamin D status at baseline and disease motor severity at 36 months.

AB - BACKGROUND: Previous cross-sectional studies have shown that Parkinson's disease (PD) patients have lower serum 25-hydroxy vitamin D (25(OH)D) concentrations than controls. Vitamin D deficiency was associated with increased disease severity and cognitive impairment in prevalent PD patients.OBJECTIVE: The aim of the study was to determine 25(OH)D in newly diagnosed PD and age-matched controls and to assess if there was an association with clinical outcomes (disease severity, cognition and falls) over the 36-month follow up period.METHODS: A prospective observational study of newly diagnosed PD patients in the North East of England with age-matched controls (PD, n = 145; control, n = 94). Serum 25(OH)D was assessed at baseline and 18 months. Participants underwent clinical assessment at baseline, 18 and 36 months. One hundred and ten participants with PD also took part in a prospective falls study.RESULTS: Mean serum 25(OH)D concentrations were lower in PD than control participants at baseline (44.1±21.7 vs. 52.2±22.1 nmol/L, p < 0.05) and 18 months (44.2±23.6 vs. 55.7±28.8 nmol/L, p < 0.05). Baseline serum 25(OH)D concentration, age, motor score and dosage of dopaminergic medication were significant predictors of variance of motor severity at 36 months ((ΔR2 = 0.039, F = 6.6, p < 0.01). Serum 25(OH)D was not associated with cognition or falls during the follow up period.CONCLUSIONS: Patients with incident PD had significantly lower serum 25(OH)D concentrations than age-matched controls, which may have implications in terms of bone health and fracture risk. There was a small but significant association between vitamin D status at baseline and disease motor severity at 36 months.

KW - balance

KW - cognition

KW - disease progression

KW - fall

KW - 25-hydroxy vitamin D

KW - Parkinson's disease

KW - vitamin D

U2 - 10.3233/JPD-171122

DO - 10.3233/JPD-171122

M3 - Article

C2 - 28984616

SN - 1877-7171

VL - 7

SP - 669

EP - 675

JO - Journal of Parkinson's Disease

JF - Journal of Parkinson's Disease

IS - 4

ER -

The Role of Vitamin D in Disease Progression in Early Parkinson's Disease

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this